Health Care·Life Sciences Tools & Services·$8.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.88 | N/A | -1.12% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.88 | N/A | -1.12% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions affecting performance. They highlighted a focus on efficiency and did not provide specific guidance.
Management noted that they are facing challenges in the current market environment.
They emphasized the importance of maintaining operational efficiency.
There were no significant updates on future strategies.
Bio-Techne Corp's earnings report indicates a slight miss on EPS, which contributed to a modest decline in stock price. The lack of revenue data and guidance leaves investors uncertain about future performance. Management's cautious tone suggests they are navigating a challenging market landscape.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HARTFORD INS GROUP I
Apr 29, 2013